Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea

Inclusion criteria

• Patients with culture-positive stool sample with Campylobacter concisus
• Diarrheic patients ≥ 18 years
• symptoms of diarrhea defined as three or more watery stools per day or
• two watery stools per day + at least one of the following symptoms: abdominal pain, nausea, vomiting or fever.
• Diarrheic symptoms for a minimum of 24 hours before enrollment.
• Diarrheic symptoms for a maximum of 21 days before enrollment.
• Informed oral and signed written consent, with documentation that all relevant information about the study is given to the patient.
• The patient must be willing and able to participate in the trial.

Exclusion criteria

• Hypersensitivity to azithromycin, erythromycin, macrolide or other ketolide-antibiotics
• Pregnancy or breastfeeding (if relevant).
• Culture positive stool sample with a Co-pathogen.
• Treatment with other antibiotics (in any stage 21 days before the first stool sample).
• Patients with severe liver disease.
• Patients with severe renal impairment (GFR <10 ml / min).
• Patients with congenital or documented acquired QT prolongation.
• Patients treated with other active drugs that prolong the QT interval such as: antiarrhythmics of classes IA and III, cisapride and terfenadine.
• Patients with electrolyte disorders, particularly hypokalemia and hypomagnesemia.
• Patients with clinically relevant bradycardia, arrhythmia or severe heart failure.
• Inflammatory bowel diseases
• Chronic diarrhea of known cause.
• Dementia.
• Serious illness less than 21 days from the planned entry into the study.
• Patients treated with medications that have interactions with azithromycin e.g. alkaloids, ciclosporin or amiodarone.
• Patients involved in the planning or execution of the study.